Active, not recruitingPhase 1NCT04538911

Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients

Studying Tuberculosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Principal Investigator
Shuihua Lu, Bachelor
Shenzhen Third People's Hospital
Intervention
BCG-PPD(drug)
Enrollment
60 enrolled
Eligibility
65 years · All sexes
Timeline
2021 – 2025

Study locations (1)

Collaborators

Shenzhen Third People's Hospital · Beijing Kangterike Statistical Technology Co., Ltd. · Wuhan Pulmonary Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04538911 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis →

← Back to all trials